The 25.8 Data Release includes updates to human and model studies, including SEA-AD and Diverse Cohorts.

Human

  • The AGMP BEAM Study

    This study generates lipidomics, targeted and untargeted metabolomics and metagenomics for 17 individuals, cognitively normal or diagnosed with MCI. This release provides Baker lipidomics and Nightingale NMR metabolomics from serum and CSF, UCSD untargeted metabolomics from serum, plasma and fecal samples, as well as metadata for all individuals and biospecimens.

  • The SEA-AD Study

    This study provides transcriptomic and chromatin accessibility data from single nuclei isolated from multiple brain tissues of 84 aged individuals spanning the full spectrum of Alzheimer’s disease severity and 5 neurotypical adult reference individuals. The Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) consortium includes the Allen Institute for Brain Science, the University of Washington, and Kaiser Permanente Washington Health Research Institute. 

    • This release provides multiome, single-nucleus ATACseq, and single-nucleus RNA sequencing data for caudate nucleus, angular gyrus, and insular cortex samples sourced from both SEA-AD and reference donors. It also provides additional file metadata.

  • The WHICAP_Immunoprofiling Study

    This study generates cytometric data and bulk RNAseq profiles of peripheral blood mononuclear cells (PBMC) from older individuals.

    • This release provides bulk RNA sequencing data data for peripheral blood mononuclear cells sourced from 138 individuals, as well as updated clinical metadata to reflect the new bulk RNA sequencing samples.

  • The AMP-AD_DiverseCohorts Study

    The AMP-AD Diverse Cohorts Study is a cross-consortium project generating harmonized datasets from diverse human cohorts. This study provides post-mortem multi-omic data from over 850 individuals, including 305 Black or African American individuals and 336 Hispanic or Latino individuals representing the spectrum of Alzheimer’s Disease phenotypes. Data is generated from research teams at Rush University, Emory University, the Mayo Clinic, Columbia University, and Mt Sinai Medical School.

    • This release provides lipidomics data generated by Duke University using the Metabolon assay on brain and plasma samples from existing Mayo Clinic, Mt Sinai Brain Bank, Rush University, and Emory University participants.

  • The AGMP_MARS_WISCONSIN Study

    This study provides proteomic, lipidomic and untargeted metabolomic data on individuals as part of the Microbiome in Alzheimer’s Risk Study (MARS) enrolled by the Wisconsin Alzheimer’s Disease Center.

    • This release provides new serum proteomics data generated from MARS participants.

Models

  • The Jax.IU.Pitt_5XFAD Study rerelease

    • The Jax.IU.Pitt_5XFAD Study: We have updated the IU/JAX/PITT “5XFAD deep phenotyping” study with expanded metadata and improved analyses.

  • The Jax.IU.Pitt_APOE4TREM2 Study rerelease

    • The Jax.IU.Pitt_APOE4.Trem2.R47H Study: We have updated the IU/JAX/PITT “LOAD1 deep phenotyping” study with expanded metadata and improved analyses.

  • The Jax.IU.Pitt_LOAD1.Diet Study

    The Jax.IU.Pitt_LOAD1.Diet study: This study examines how a high-fat diet (HFD) influences genetically modified mice that model Alzheimer’s Disease. Mice with specific Alzheimer’s-related genes (LOAD1.Plcg2M28L) were studied at Indiana University (IU), while others (LOAD1.Mthfr677C>T) were studied at JAX labs. Each experimental group was paired with LOAD1 control mice for comparison, with additional B6 mice as strain controls at IU. Both IU and JAX bred these mice to produce groups with three matching Alzheimer’s-related genes, enabling a more detailed analysis of HFD’s effects on disease progression.

  • The Jax.IU.Pitt_LOAD2.PrimaryScreen Study 

    The JAX.IU.Pitt_LOAD2.Primary Screen Study: The purpose of this study is to provide initial characterization of novel mouse models of late-onset Alzheimer’s disease designed by MODEL-AD and created at The Jackson Laboratory. These new mouse strains express combinations of risk alleles identified from human LOAD data repositories. Here, all mice express APOE4, Trem2*R47H, and hAβ genes- which has been termed “LOAD2” background. Ten additional genes [performed at The Jackson Laboratory (Bin1, Cd2ap, Epha1, Il1rap, Ptprb, and Tau-H2) or Indiana University (Adamts4, Il34, Ptk2b, and Scimp)] were all screened on this background, and compared to “LOAD2” and B6 control cohorts, for behavioral phenotypes and molecular signatures associated with disease severity. Each strain was aged in cohorts to 4 months and 12e months of age, tested and sampled.

  • The Jax.IU.Pitt_LOAD2.StrainValidation Study 

    TheJax.IU.Pitt_LOAD2.StrainValidation Study: The aim of this study is to generate novel in vivo mouse models for late-onset Alzheimer’s disease (LOAD) and to validate the genotypes of the new strains. The LOAD-related genetic variants were identified and prioritized based on significance in multiple studies, predicted effect on biological function, human-mouse sequence conservation, and differential expression in AD. Target variants were modeled by CRISPR/Cas9 variant knock-in or gene knock-out, depending on the predicted variant effect. All variants were introduced on the triple homozygous B6J.APOE4.Trem2*R47H.hAPP (“LOAD2”) sensitized background strain (which includes: Adamts4 enhancer KO, Bin1 intron 1 SNP, Cd2ap promoter SNP, Epha1 exon 1 SNP, Il1rap Exon 3 KO, Il34*Y213, Ptk2b intron 5 SNP, Ptprb*D57N, Scimp upstream SNP, and Tau-H2). RNA-Seq transcriptomics analysis was used for genotyping and to quantify the expression levels of the targeted genes. Protein expression levels of the targeted genes were determined by Western Blot analysis.Jax.IU.Pitt_5XFAD re-release